Sandostatin^® LAR^® Acromegaly Virtual Booth

Sandostatin LAR Virtual Booth matches your experience to that of attendees at international scientific congresses.

Move your mouse below for more information: enter by clicking on the numbered exhibit panels or the titles listed below the Booth.

1. Efficacy: Significant improvements in 5 common symptoms of acromegaly¹
2. Control: Effectively reduces GH and normalises IGF-1 2
3. Safety: Sandostatin LAR is well tolerated with an established safety profile ^3,4
4. Evidence: Meet the goals of therapy with Sandostatin LAR
5. Reduction: Sandostatin LAR provides significant tumour volume reduction⁴
6. Convenience: The home administration programme* provides easier access to treatment
7. Experience: Well-established efficacy and safety profile of Sandostatin LAR^3,4

* Programme may not be available in all countries. Please consult your local Novartis representative in your respective countries.

References: 1. Lancranjan I, Atkinson AB; and the Sandostatin^® LAR^® Group. Results of a European multicentre study with Sandostatin^® LAR^® in acromegalic patients. Pituitary. 1999;1:103-111. 2. Cozzi R, Attanasio R, Montini M, et al. Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin Endocrinol Metab. 2003;88:3090-3098. 3. Data on file, Novartis Pharma AG. 4. Sandostatin^® LAR^® Basic Prescribing Information, Novartis Pharma AG.